Sandoz Canada Inc. Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Sandoz Canada Inc. Pharmaceutical Import Records from India — 2 Products, $4.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sandoz Canada Inc. — Pharmaceutical Importer Profile (2026) | 2 Products, $4.3M Trade | TransData Nexus

Sandoz Canada Inc.

Pharmaceutical Importer · Canada · Gastrointestinal Focus · $4.3M Total Trade · DGFT Verified

Sandoz Canada Inc. is a pharmaceutical importer based in Canada with a total trade value of $4.3M across 2 products in 2 therapeutic categories. Based on 101 verified import shipments from Indian Customs (DGFT) records, Sandoz Canada Inc. is the #1 buyer in 1 product including Lansoprazole. Sandoz Canada Inc. sources from 6 verified Indian suppliers, with Sandoz Private Limited accounting for 59.4% of imports.

Sandoz Canada Inc. — Import Portfolio & Supplier Network

Sandoz Canada Inc. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sandoz Canada Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$23.3M	682	59.4%
Alembic Pharmaceuticals Limited	$15.0M	688	38.4%
Intas Pharmaceuticals Limited

What Formulations Does Sandoz Canada Inc. Import?

Formulation	Value	Ships
Sandoz fesoterodine fumarate	$732.1K	30
Material no. - 44100995 sitaglip+metf	$644.9K	15
Sandoz lurasidone (lurasidone	$573.4K	17
Material no. - 44100861 sitaglip+metf	$500.0K	10
Lansoprazole hgc 30MG in91 sh ms material no. -	$432.2K	11
Lansoprazole hgc 30MG in91 sh ms	$350.0K	7
Sitaglip+metf sdz 50+1000MG 360fct bo	$335.2K	7
Sitaglip+metf sdz 50+1000MG 60prt bo camaterial no. -	$321.1K	7
Material no- 44100995 sitaglip+metf sdz50+1000MG 360fct bo	$280.4K	6
Sitaglip+metf sdz 50+1000MG 360fct bo camaterial no. -	$280.1K	6
Material no. - 44100966 sitaglip+metf	$277.7K	7
Material no-44100966 sitaglip+metf sdz 50+1000MG 60fct bo	$276.3K	6
Material no. - 44101245 sitagliptin	$250.5K	6
Valsart+hct fct 160+25MG in91 sh ca	$250.0K	5
Tacrolimus sdz 1MG 100hgc bo ca	$250.0K	5

Sandoz Canada Inc. imports 755 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lansoprazole	Gastrointestinal	$2.5M	49	0.6%	1
2	Valsartan	Cardiovascular	$1.9M	52	1.0%	18

Sandoz Canada Inc. imports 2 pharmaceutical products across 2 categories into Canada totaling $4.3M. The company is the #1 buyer for 1 product: Lansoprazole.

Sandoz Canada Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sandoz Canada Inc. is a prominent pharmaceutical company specializing in the development, manufacturing, and distribution of generic pharmaceuticals and biosimilars within Canada. As a subsidiary of Sandoz International GmbH, which is part of the Novartis Group, Sandoz Canada operates under the global leadership of Sandoz, a pioneer in generic and biosimilar medicines. The company is headquartered in Saint-Hubert, Quebec, and has a significant presence in the Canadian pharmaceutical market.

Sandoz Canada's product portfolio encompasses a wide range of therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. The company is recognized for its commitment to improving patient access to affordable medicines through the provision of high-quality generic and biosimilar products.

2Distribution Network

Sandoz Canada Inc. maintains a robust distribution network to ensure the efficient delivery of its pharmaceutical products across the country. The company's primary distribution center is located in Saint-Hubert, Quebec, serving as the central hub for logistics and supply chain operations. This strategic location facilitates timely distribution to various regions within Canada, ensuring that healthcare providers and patients have access to essential medications.

While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, Sandoz Canada's established infrastructure and partnerships with logistics providers enable the company to effectively manage its distribution operations. The company's geographic coverage extends throughout Canada, ensuring that its products are accessible to a wide range of healthcare facilities and pharmacies.

3Industry Role

Sandoz Canada Inc. plays a pivotal role in Canada's pharmaceutical supply chain as a primary wholesaler and distributor of generic pharmaceuticals and biosimilars. The company is recognized as the second-largest generic pharmaceutical and biosimilars company in Canada, underscoring its significant presence in the market.

In addition to its wholesale and distribution activities, Sandoz Canada has expanded its portfolio to include medical cannabis products. In June 2018, the company finalized an alliance with Tilray, a Health Canada-licensed producer of medical cannabis, becoming the first Canadian pharmaceutical company to enter the medical cannabis field.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sandoz Canada Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sandoz Canada Inc. demonstrates a high degree of sourcing concentration in its procurement of pharmaceutical products from India. The company's total import value from India amounts to $4.3 million USD, encompassing 101 shipments and 755 unique formulations across two therapeutic categories: gastrointestinal and cardiovascular. The top five imported products are Lansoprazole ($2.5 million, 0.6% share) and Valsartan ($1.9 million, 1.0% share), with Lansoprazole being the leading product.

The sourcing pattern indicates a strategic choice to concentrate procurement from a select group of suppliers. The top six verified Indian suppliers are:

Sandoz Private Limited: $23.3 million (59.4% of total imports)
Alembic Pharmaceuticals Limited: $15.0 million (38.4%)
Intas Pharmaceuticals Limited: $352K (0.9%)
Strides Pharma Science Limited: $285K (0.7%)
AET Laboratories Private Limited: $113K (0.3%)

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada, which is responsible for ensuring that all pharmaceutical products meet the necessary safety, efficacy, and quality standards. The Food and Drugs Act and its associated regulations govern the importation, distribution, and sale of pharmaceutical products in Canada.

For Indian generics to be marketed in Canada, they must undergo a rigorous evaluation process to obtain a Notice of Compliance (NOC) from Health Canada. This process involves demonstrating that the generic product is bioequivalent to the reference brand-name drug and meets all applicable regulatory requirements.

2Import Licensing & GMP

Import licensing requirements in Canada stipulate that all pharmaceutical products, including generics, must be imported by a licensed establishment. Sandoz Canada Inc., as a licensed importer, is authorized to import pharmaceutical products into the country.

Good Manufacturing Practice (GMP) certification is essential for ensuring product quality. Health Canada recognizes GMP certifications from various regulatory bodies, including the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian manufacturers seeking to supply Sandoz Canada must hold valid GMP certifications from these recognized authorities to ensure compliance with Canadian standards.

Sandoz Canada Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sandoz Canada Inc.'s focus on gastrointestinal and cardiovascular therapeutic areas aligns with significant market demand for treatments in these categories. The company's importation of Lansoprazole and Valsartan addresses prevalent health conditions such as acid reflux and hypertension, respectively. By concentrating on these areas, Sandoz Canada aims to provide accessible and effective treatment options to a large patient population.

2Sourcing Profile

Sandoz Canada's sourcing strategy emphasizes the procurement of generic drugs and biosimilars from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, reflects a focus on ready-to-market products that meet Canadian regulatory standards.

3Market Positioning

With its diverse product mix, Sandoz Canada Inc. serves multiple segments of the Canadian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's ability to provide a wide range of generic and biosimilar products positions it as a key player in enhancing access to affordable medications across the country.

Seller's Guide — How to Become a Supplier to Sandoz Canada Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Sandoz Canada Inc.'s supply chain, particularly if they can offer competitive pricing, high-quality products, and compliance with Canadian regulatory standards. Identifying gaps in Sandoz Canada's current sourcing, such as unmet demand for specific formulations or therapeutic areas, can provide avenues for new suppliers to establish partnerships.

2Requirements & Qualifications

Indian exporters seeking to supply Sandoz Canada Inc. must obtain GMP certifications from recognized authorities, such

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Sandoz Canada Inc.

What products does Sandoz Canada Inc. import from India?

Sandoz Canada Inc. imports 2 pharmaceutical products across 2 categories. Top imports: Lansoprazole ($2.5M), Valsartan ($1.9M).

Who supplies pharmaceuticals to Sandoz Canada Inc. from India?

Sandoz Canada Inc. sources from 6 verified Indian suppliers. The primary supplier is Sandoz Private Limited (59.4% of imports, $23.3M).

What is Sandoz Canada Inc.'s total pharmaceutical import value?

Sandoz Canada Inc.'s total pharmaceutical import value from India is $4.3M, based on 101 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sandoz Canada Inc. focus on?

Sandoz Canada Inc. imports across 2 categories. The largest: Gastrointestinal (56.6%), Cardiovascular (43.4%).

Get Full Sandoz Canada Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.